VERTEX PHARMACEUTICALS INCORPORATED |
|
|
130 WAVERLY STREET · CAMBRIDGE, MA 02139-4242 |
|
TEL. 617.444.6100 FAX 617.444-6483 |
|
http://www.vrtx.com |
September 20, 2007
Delivered by EDGAR
Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 6010
Washington, DC 20549
Attn: Tim Buchmiller, Senior Attorney
Re: |
Vertex Pharmaceuticals Incorporated |
|
|
Definitive Proxy Statement |
|
|
Filed April 12, 2007 |
|
|
File No. 000-19319 |
|
Ladies and Gentlemen:
This letter relates to (i) comments from the staff of the Securities and Exchange Commission (the Commission) to Vertex Pharmaceuticals Incorporated (the Company) set forth in the staffs letter to Dr. Joshua Boger, dated August 21, 2007 (the Comment Letter), regarding the Companys Definitive Proxy Statement, which was filed with the Commission on April 12, 2007, and (ii) a conversation between a representative of the Companys legal department and a representative of the staff of the Commission, which occurred on September 12, 2007. During such conversation, the staff of Commission (i) requested that the Company file this letter with the Commission on or before September 21, 2007 and (ii) confirmed that the Companys proposed schedule for responding to the Comment Letter, as set forth in this letter, was acceptable to the Commission.
The Company hereby confirms:
1) That the Company has received the Comment Letter.
2) That the Company is in the process of drafting its response to the Comment Letter.
3) That the Company desires to discuss its response to the Comment Letter at the regularly scheduled October 17, 2007 meeting of the Companys Management Development and Compensation Committee.
4) That the Company will file its response to the Comment Letter via EDGAR on or before October 23, 2007.
Please contact me at 617-444-6417 in the event that you have any questions or concerns with respect to this matter. In the event that I am not available, please contact my colleague, Valerie Andrews, at 617-444-6227.
|
Very truly yours, |
|
|
|
|
|
|
/s/ Kenneth S. Boger |
|
|
|
|
|
Kenneth S. Boger |
|
|
Senior Vice President and General Counsel |
2